224 related articles for article (PubMed ID: 30939095)
1. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.
Tchekmedyian V; Sherman EJ; Dunn L; Tran C; Baxi S; Katabi N; Antonescu CR; Ostrovnaya I; Haque SS; Pfister DG; Ho AL
J Clin Oncol; 2019 Jun; 37(18):1529-1537. PubMed ID: 30939095
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503).
Iwasa S; Okita N; Kuchiba A; Ogawa G; Kawasaki M; Nakamura K; Shoji H; Honma Y; Takashima A; Kato K; Hamaguchi T; Boku N; Yamada Y
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817132
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors.
Al-Toubah T; Schell MJ; Morse B; Haider M; Valone T; Strosberg J
ESMO Open; 2024 Apr; 9(4):102386. PubMed ID: 38507897
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Hanna GJ; Ahn MJ; Muzaffar J; Keam B; Bowles DW; Wong DJ; Ho AL; Kim SB; Worden F; Yun T; Meng X; Van Tornout JM; Conlan MG; Kang H
Clin Cancer Res; 2023 Nov; 29(22):4555-4563. PubMed ID: 37643133
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.
Niho S; Sato J; Satouchi M; Itoh S; Okuma Y; Mizugaki H; Murakami H; Fujisaka Y; Kozuki T; Nakamura K; Machida R; Ohe Y; Tamai T; Ikezawa H; Yamamoto N
Lung Cancer; 2024 May; 191():107557. PubMed ID: 38626709
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.
Dillon PM; Petroni GR; Horton BJ; Moskaluk CA; Fracasso PM; Douvas MG; Varhegyi N; Zaja-Milatovic S; Thomas CY
Clin Cancer Res; 2017 Aug; 23(15):4138-4145. PubMed ID: 28377480
[No Abstract] [Full Text] [Related]
7. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
Ferrarotto R; Sousa LG; Feng L; Mott F; Blumenschein G; Altan M; Bell D; Bonini F; Li K; Marques-Piubelli ML; Dal Lago EA; Johnson JJ; Mitani Y; Godoy M; Lee A; Kupferman M; Hanna E; Glisson BS; Elamin Y; El-Naggar A
J Clin Oncol; 2023 May; 41(15):2843-2851. PubMed ID: 36898078
[TBL] [Abstract][Full Text] [Related]
8. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review.
Crotty P; Kari K; Hughes GK; Ladd C; McIntire R; Gardner B; Peña AM; Ferrell S; Tuia J; Cohn J; Haslam A; Prasad V; Vassar M
Target Oncol; 2024 Mar; 19(2):161-173. PubMed ID: 38466535
[TBL] [Abstract][Full Text] [Related]
9. Vascular Endothelial Growth Factor Receptor Inhibitors for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis.
Hoff CO; Manzi J; Lazar Neto F; Ferrarotto R
JAMA Otolaryngol Head Neck Surg; 2024 May; ():. PubMed ID: 38814585
[TBL] [Abstract][Full Text] [Related]
10. Systemic and Targeted Therapies in Adenoid Cystic Carcinoma.
Kacew AJ; Hanna GJ
Curr Treat Options Oncol; 2023 Jan; 24(1):45-60. PubMed ID: 36637743
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials.
Kim Y; Keam B; Kang EJ; Kim JS; Kim HR; Lee KW; Kwon JH; Lee KE; Yang Y; Choi YH; Kim MK; Ji JH; Yun T; Choi MY; Lee KH; Kim SB; Ahn MJ
Cancer Res Treat; 2024 Apr; ():. PubMed ID: 38637966
[TBL] [Abstract][Full Text] [Related]
12. First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report.
Hoff CO; Dal Lago EA; Siqueira JM; de Sousa LG; El-Naggar AK; Ahnert JR; Ferrarotto R
JCO Precis Oncol; 2024 Apr; 8():e2300633. PubMed ID: 38579194
[TBL] [Abstract][Full Text] [Related]
13. Hand Foot Syndrome Induced by Lenvatinib - A Case Report.
Rangshahi K; Nanda S; Gurunthalingam MP; Katiyara V; Thangaraju P; Gaikwad NR
Curr Drug Saf; 2024 Mar; ():. PubMed ID: 38486391
[TBL] [Abstract][Full Text] [Related]
14. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.
Locati LD; Galbiati D; Calareso G; Alfieri S; Singer S; Cavalieri S; Bergamini C; Bossi P; Orlandi E; Resteghini C; Platini F; Granata R; Quattrone P; Mancinelli M; Mariani L; Lo Vullo S; Licitra LF
Cancer; 2020 Jan; 126(9):1888-1894. PubMed ID: 32031693
[TBL] [Abstract][Full Text] [Related]
15. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.
Ho AS; Ochoa A; Jayakumaran G; Zehir A; Valero Mayor C; Tepe J; Makarov V; Dalin MG; He J; Bailey M; Montesion M; Ross JS; Miller VA; Chan L; Ganly I; Dogan S; Katabi N; Tsipouras P; Ha P; Agrawal N; Solit DB; Futreal PA; El Naggar AK; Reis-Filho JS; Weigelt B; Ho AL; Schultz N; Chan TA; Morris LG
J Clin Invest; 2019 Oct; 129(10):4276-4289. PubMed ID: 31483290
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.
Locati LD; Cavalieri S; Bergamini C; Resteghini C; Alfieri S; Calareso G; Bossi P; Perrone F; Tamborini E; Quattrone P; Granata R; Galbiati D; Platini F; Orlandi E; Mariani L; Licitra L
Head Neck; 2019 Oct; 41(10):3670-3676. PubMed ID: 31355973
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Rodriguez CP; Wu QV; Voutsinas J; Fromm JR; Jiang X; Pillarisetty VG; Lee SM; Santana-Davila R; Goulart B; Baik CS; Chow LQM; Eaton K; Martins R
Clin Cancer Res; 2020 Feb; 26(4):837-845. PubMed ID: 31796519
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.
Mahmood U; Bang A; Chen YH; Mak RH; Lorch JH; Hanna GJ; Nishino M; Manuszak C; Thrash EM; Severgnini M; Sanborn M; Sridharan V; Margalit DN; Tishler RB; Busse PM; Willers H; Mamon HJ; Yoo HJ; Pai SI; Wirth LJ; Haddad RI; Chau NG; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2021 Jan; 109(1):134-144. PubMed ID: 32781104
[TBL] [Abstract][Full Text] [Related]
19. Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands.
Cavalieri S; Mariani L; Vander Poorten V; Van Breda L; Cau MC; Lo Vullo S; Alfieri S; Resteghini C; Bergamini C; Orlandi E; Calareso G; Clement P; Hauben E; Platini F; Bossi P; Licitra L; Locati LD
Eur J Cancer; 2020 Sep; 136():35-42. PubMed ID: 32629365
[TBL] [Abstract][Full Text] [Related]
20. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
